• Novel product in development for the treatment of people living with Parkinson's disease
• Biotie receives USD 20 million license fee payment
• Original agreement modified: Biotie to conduct phase 3 development
Brussels (Belgium), February 26th, 2013, 1800 CEST – regulated information – UCB and Biotie Therapies announced today that UCB has licensed worldwide exclusive rights to Biotie's tozadenant (SYN115), a selective inhibitor of the adenosine 2a receptor, currently in development for the treatment of Parkinson’s disease. As a result, Biotie will receive a one-time fee payment of USD 20 million from UCB. In addition, the parties have amended their original licence agreement, such that Biotie will now conduct phase 3 development of tozadenant in return for additional payments from UCB relating to defined development, regulatory and commercialization milestones.
"UCB is committed to improving the lives of people with Parkinson’s disease and currently provides Neupro® a transdermal dopamine agonist for the symptomatic treatment of all stages of idiopathic Parkinson’s disease," said Professor Dr Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President UCB. "Biotie is a valuable partner and the decision to in-license follows the positive top-line results of the phase 2b study. We were impressed by the performance of Biotie and decided that they are the ideal party to continue to spearhead the development of tozadenant. We look forward to collaborating with Biotie in the on-going clinical development. With the addition of the novel compound tozadenant to UCB’s development portfolio we should be able to further contribute to the advancement of the treatment and care for people living with Parkinson’s disease."
The phase 2b study was a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of tozadenant as adjunctive therapy in levodopa-treated Parkinson's patients with end of dose wearing off. Results from the phase 2b study are expected to be presented at upcoming medical conferences and in scientific publications. Patient enrolment in the phase 3 program is currently planned to commence by the first half of 2015.
The original agreement between UCB and Biotie was announced in 2010. Under the terms of the original agreement UCB will make an immediate one-time payment of USD 20 million to Biotie and Biotie will remain eligible to a potential additional USD 340 million in future milestone payments. Under the revised agreement, Biotie will be eligible for additional payments in the low triple digit millions in total over the next six years based on the successful completion of defined development, regulatory and commercialization milestones. Further financial details of the agreement are not disclosed. UCB and Biotie will collaborate on the on-going clinical development and UCB will be responsible for the manufacture and commercialization of tozadenant.
"We are thrilled with the opportunity to continue the development of tozadenant in partnership with UCB", said Timo Veromaa, President and Chief Executive Officer of Biotie. "We are encouraged by the vote of confidence provided to us by UCB to continue with us the development of tozadenant and the very significant incremental financial resources that we will be given to complete the clinical work."
Parkinson’s disease is a chronic, degenerative neurological disease. It is commonly associated with movement (motor) symptoms such as tremors (uncontrollable shaking), rigidity (stiffness or muscle tensing) and bradykinesia (slowness and loss of spontaneous movement), but also commonly causes underlying symptoms such as mood and cognitive impairment, pain, depression and fatigue.
About tozadenant (SYN115)
Tozadenant is an orally administered, selective inhibitor of the adenosine 2a (A2a) receptor being developed initially for the treatment of Parkinson’s disease. A2a receptors are expressed in high concentration in the striatum of the brain and are thought to play an important role in regulating motor function. Tozadenant blocks the effect of endogenous adenosine at the A2a receptors, resulting in the potentiation of the effect of dopamine and inhibition of the effect of glutamate at the mGluR5 receptor.
For further information
Antje Witte, Investor Relations UCB
T +32.2.559.9414, firstname.lastname@example.org
France Nivelle, Global Communications, UCB
T +32.2.559.9178, email@example.com
Eimear O Brien, Director, Brand Communications UCB
T +32.2.559.9271, firstname.lastname@example.org
Laurent Schots, Media Relations, UCB
T +32.2.559.9264, email@example.com
Virve Nurmi, Investor Relations Manager Biotie
T +358 2 274 8900, firstname.lastname@example.org
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).
ABOUT BIOTIE (www.biotie.com)
Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease. The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential.
Biotie's most advanced product, Selincro(TM) (nalmefene), licensed to Lundbeck A/S, has on 14 December 2012 received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorization of Selincro(TM) for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. In addition, Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant which has successfully completed a Phase 2b study in 420 patients with advanced Parkinson's disease. Biotie shares are listed on NASDAQ OMX Helsinki Ltd. Symbol: BTH1V
UCB Forward-Looking Statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.